Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03457233
Other study ID # 31
Secondary ID
Status Recruiting
Phase N/A
First received February 25, 2018
Last updated March 6, 2018
Start date January 3, 2015
Est. completion date March 2018

Study information

Verified date March 2018
Source Cairo University
Contact Ahmed Maged, MD
Phone +2001005227404
Email prof.ahmedmaged@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Induction of ovulation cycle:

1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu.

2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger.

4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection

5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval.

6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization.

7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy).

8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100


Description:

Induction of ovulation cycle:

1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu.

2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger.

4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection

5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval.

6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization.

7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy).

8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100


Recruitment information / eligibility

Status Recruiting
Enrollment 185
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 44 Years
Eligibility Inclusion Criteria:

- 4- Poor responder according to ESHRE consensus; in which at least 2 of the following should be present: Advanced maternal age (= 40 years old) or any other risk factor A previous poor ovarian response (cycles cancelled or = 3 oocytes with a conventional protocol)An abnormal ovarian reserve test (ORT); antral follicle count (AFC) < 5-7 follicles or anti-mullerian hormone (AMH) =0.5- 1.1 ng/ml In the absence of advanced maternal age or abnormal ORT, two previous episodes of poor ovarian response after maximal stimulation patients are also considered poor responders according to ESHRE consensus.

Presence and Adequate visualization of both ovaries Uterine cavity within normal anatomy assessed with HSG, hysteroscopy and TVUS

Exclusion Criteria:

Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like:

1. Severe male factor .

2. Uterine factor (eg: fibroid, polyp, Ashermann, .. etc)

3. Immunological disorder (eg: SLE, APS, … etc)

4. Thyroid or adrenal dysfunction

5. Neoplasia (especially: hypothalamic, pit, ovarian)

6. Women diagnosed with PCOS according to Rotterdam criteria

7. Hydrosalpinx that hasn't been surgically removed or ligated.

8. Untreated hyperprolactinemia

9. Abnormal bleeding disorder

10. Hepatic or renal dysfunction

11. Hypersenstivity to study medication ( GNRH antagonist)

12. Need to take medication that can influence ovarian stimulation

13. Endometriosis grade 3 or 4

14. Ovarian cyst> 10 cm.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gonadotropins
1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
GNRH antagonist
cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
Human chorionic gonadotropin Chorimon
10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
Natural progesterone
400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing

Locations

Country Name City State
Egypt Kasr Alainy medical school Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pregnancy rate appearance of intrauterine gestational sac by transvaginal ultrasound 4 weeks after HCG triggering
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03684824 - Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment N/A
Not yet recruiting NCT03683043 - Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer Phase 4
Recruiting NCT02329197 - Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure Phase 4
Completed NCT02764255 - Embryoscope and Reproductive Outcome N/A
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A
Completed NCT02674178 - FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Phase 4
Completed NCT01576991 - Telomeres and Reproduction in Women N/A
Completed NCT02660125 - Endometrial Injury and Implantation Rates Before First ICSI Cycle N/A
Completed NCT03402620 - Poor Responders Infertile Patients -A Great Clinical Challenge N/A
Completed NCT03831542 - Effect of Follicular Flushing in Patients With Mono-follicular Growth Undergoing In Vitro Fertilization
Not yet recruiting NCT03263299 - Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol Phase 4
Completed NCT03118830 - Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Phase 4
Recruiting NCT02383394 - Factors Associated With Pregnancy Loss in IVF Women N/A